Original contribution
Radiotherapy alone in carcinoma of the intact uterine cervix according to G. H. Fletcher guidelines: A french cooperative study of 1383 cases

https://doi.org/10.1016/0360-3016(88)90080-6Get rights and content

Abstract

A French Cooperative study of 1383 cases with invasive carcinoma of the intact uterine cervix treated with radiation therapy alone, using the guidelines provided by G. H. Fletcher led to the following conclusions: The techniques of treatment were easily reproducible in 9 French centers, working in a prospective cooperative study; Results similar to those of the original study were achieved in Stages I and IIA (MDAH substaging) with a locoregional failure rate of 7%; In Stage IIB, the locoregional failure rate of 16% is also comparable in both studies; Locoregional failures in Stage 1111 are slightly lower than those reported in Houston, probably reflecting differences in patient's prognostic factors in France and Texas; The 5-year survival rate obtained in advanced Stages (UICC FIGO staging) are among the highest in the literature (76% in Stage IIb, 62% in Stage IIIa and 50% in Stage IIIb); The rate of severe complications remains acceptable and decreased throughout the study thanks to a better use of computer dosimetry.

References (23)

  • G.H. Fletcher et al.

    Overall results in radiotherapy for carcinoma of the cervix: Modern treatment

    Clin. Obst. Gynec.

    (1968)
  • Cited by (157)

    • Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial

      2021, Brachytherapy
      Citation Excerpt :

      Brachytherapy is quintessential and a good quality intracavitary brachytherapy has shown to improve both local control and disease free survival. (3,4) Low-dose-rate (LDR) intracavitary brachytherapy has been the time-tested brachytherapy dose rate system for cervical cancer (5). Since the introduction of high-dose-rate (HDR) in late 1980′s, there has been a steady shift in brachytherapy dose rate system with > 85% utilization rates reported. (6)

    • Evaluation of outcomes in patients of cervical Cancer with lower one third vaginal involvement: A single institutional experience

      2020, Gynecologic Oncology
      Citation Excerpt :

      In our study, we have compared survival of IIIA and IIIB patients with lower vaginal involvement for this cohort. Five-year OS of stage IIIA patients in previous studies was higher than that of stage IIIB with 58%–62% and 34%–50% [9,10] [7,8] respectively which is matching with our results [3 year DFS (71% vs 56%; p = .02) and 3 years OS (76% vs 66%; p = .01) on univariate analysis]. On multivariate analysis, we did not find any significant difference in survival between two groups with trend of better survival in stage IIIA group as compared to stage IIIB.

    • Cervical Cancer

      2015, Clinical Radiation Oncology
    View all citing articles on Scopus
    View full text